You are here

painkillers

FDA declines to approve Insys Therapeutic's opioid painkiller

FDA declines to approve Insys Therapeutic's opioid painkiller

Reuters

INSYS Therapeutics

Flag link:

Another cheap, old drug is being freshened up for brand pricing in the US — and shares soar

Another cheap, old drug is being freshened up for brand pricing in the US — and shares soar

Endpoints

Avenue Therapeutics

Flag link:

Pharma turns to new pain options amid opioid crisis

Pharma turns to new pain options amid opioid crisis

Biopharma Dive

abuse deterrents

Flag link:

Lilly's bet on pain stands out amid bare pharma pipeline

Lilly's bet on pain stands out amid bare pharma pipeline

Biopharma Dive

Flag link:

This Biotech Stock Catapulted After Its Pain Drug Trumped A Key Rival

This Biotech Stock Catapulted After Its Pain Drug Trumped A Key Rival

Investors Business Daily

Heron Pharmaceuticals

Flag link:

Healthcare on the Hill - a bill that would classify all opioid mu receptor agonists schedule I (H.R.5298)

Healthcare on the Hill - a bill that would classify all opioid mu receptor agonists schedule I (H.R.5298)

CP Wire

Healthcare on the Hill

mu receptor agonists

Flag link:

Physicians And Patients Finally Avoiding Horizon's Expensive, Low-Value Pain Drugs Duexis And Vimovo

Physicians And Patients Finally Avoiding Horizon's Expensive, Low-Value Pain Drugs Duexis And Vimovo

Forbes

Flag link:

What’s the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

What’s the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

Endpoints

drug development

Flag link:

Racing to replace opioids, biopharma is betting on pain drugs with a checkered past

Racing to replace opioids, biopharma is betting on pain drugs with a checkered past

Stat

Flag link:

Neurontin prescriptions surge amid opioid crisis

Neurontin prescriptions surge amid opioid crisis

Reuters

Flag link:

Ex-Pfizer CEO’s startup Centrexion gets $67M for PhIII painkiller

Ex-Pfizer CEO’s startup Centrexion gets $67M for PhIII painkiller

Endpoints

clinical trials

Flag link:

A scrappy upstart in the pain pill business takes on mighty Purdue Pharma

A scrappy upstart in the pain pill business takes on mighty Purdue Pharma

Stat

Collegium Pharmaceutical

Flag link:

Drugstore pain pills as effective as opioids in ER patients

Drugstore pain pills as effective as opioids in ER patients

Stat

emergency medicine

Flag link:

In a new setback, FDA kicks back AcelRx’s application for pain med — shares tank again

In a new setback, FDA kicks back AcelRx’s application for pain med — shares tank again

Endpoints

Flag link:

Why AcelRx Pharmaceuticals Inc Jumped Higher Today

Why AcelRx Pharmaceuticals Inc Jumped Higher Today

Motley Fool

Flag link:

Daiichi Sankyo punts $650M collaboration pact as Charleston Labs preps a comeback attempt on spurned pain drug

Daiichi Sankyo punts $650M collaboration pact as Charleston Labs preps a comeback attempt on spurned pain drug

Endpoints

Charleston Laboratories

Flag link:

Opioid drugmakers may have to slash production under new DEA proposal

Opioid drugmakers may have to slash production under new DEA proposal

BioPharma Dive

drug manufacturing

Flag link:

Partnering to Provide a Non-Opioid Pain Control Option for Orthopedic Patients

Partnering to Provide a Non-Opioid Pain Control Option for Orthopedic Patients

Qmed

post-surgical pain

Flag link:

New Pain Drug Likely To Face Price Challenges From Payers

New Pain Drug Likely To Face Price Challenges From Payers

Forbes

osteoarthritis of the knee

Flag link:

Insys's 'reckless' Subsys marketing led to patient's death, lawsuit alleges

Insys's 'reckless' Subsys marketing led to patient's death, lawsuit alleges

Fierce Pharma

Flag link:

Pages